Skip to search formSkip to main contentSkip to account menu

Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling

TLDR
It is demonstrated that aberrant sensing of nucleic acids can cause immune upregulation and heterozygous mutations in the cytosolic double-stranded RNA receptor gene IFIH1 (also called MDA5) cause a spectrum of neuroimmunological features consistently associated with an enhanced interferon state.
View on Nature (opens in a new tab)

Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment

TLDR
It is proposed that the Th17 phenotype may be unstable and that Th17 cells may convert to Th17/1 and Th1 cells in human arthritis, and therefore therapies targeting the induction of Th 17 cells could also attenuate Th17 or Th1 effector populations within the inflamed joint.
View on Publisher (opens in a new tab)

Anti-inflammatory and immunosuppressive drugs and reproduction

TLDR
Benefits of anti-inflammatory, immunosuppressive and biological drugs during pregnancy and lactation, effects of these drugs on male and female fertility and possible long-term effects on infants exposed to drugs antenatally are discussed.
View on Springer (opens in a new tab)

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

TLDR
Anakinra treatment is effective in SJIA, at least in the short term, and is associated with normalisation of blood gene expression profiles in clinical responders and induces a de novo IFN signature.
View on BMJ (opens in a new tab)

COVID-19 infection and rheumatoid arthritis: Faraway, so close!

View on Elsevier (opens in a new tab)

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

TLDR
These two phase 3 studies show the efficacy and safety of canakinumab in systemic JIA with active systemic features, and among the 100 patients who underwent randomization in the withdrawal phase, the risk of flare was lower among patients who continued to receive canakinUMab than among those who were switched to placebo.
View on PubMed (opens in a new tab)

Clinical outcome in children with chronic recurrent multifocal osteomyelitis.

TLDR
Clinical outcome of children with CRMO is generally good, but a sizeable proportion of patients have active disease at follow-up, and a minority of patients can have a severe and prolonged disease course despite intensive treatments.
View on PubMed (opens in a new tab)

Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry

TLDR
Clinical and laboratory characterization of patients with Pediatrics implies some important differences between antiphospholipid syndrome in pediatric and adult populations, and comparisons between children with primary antiph phospholipids syndrome and antiphphospholIPid syndrome associated with autoimmune disease have revealed certain differences that suggest 2 distinct subgroups.
View on Publisher (opens in a new tab)

Neonatal lupus syndromes.

View on PubMed (opens in a new tab)

Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells

TLDR
Assessing a panel of T‐cell clones as well as CD161+ or CD161− CD4+ T cells derived ex vivo from the circulation of healthy subjects or the synovial fluid of patients with juvenile idiopathic arthritis shows that nonclassic Th1 cells can be identified based on CD161 expression, aswell as the consistent expression of retinoic acid orphan receptor C, IL‐17 receptor E, CCR6, and IL‐4‐induced gene 1.
View on Wiley (opens in a new tab)
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)